Prevest Denpro Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 19 Jul 2026 | Healthcare Equipment & Supplies | Market Cap: ₹458 Cr
The company posted a 13% sales growth in FY 2025, surpassing the global dental market growth forecast of 6-8%. - They aim for higher growth in coming years by expanding diversified product lines like oral care products, 3D printers, and 3D resins. - The growth is driven by strengthening domestic market focus while maintaining export and international presence. - Efforts to penetrate rural markets and metro areas are ongoing, with improved dealer/distributor appointments. - Launch of new products like 3D printers is planned aggressively in the current year to boost revenue. - The U.S. The company reported a 13.6% revenue growth for FY 2024-25, with EBITDA margins steady around 39% and PAT growth of 12.5%, signaling stable profitability.
From Prevest Denpro Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹405
Market Cap
₹458 Cr
P/E Ratio
21.4
How does Prevest Denpro Ltd rank in Healthcare Equipment & Supplies?
Compare Prevest Denpro Ltd against every Healthcare Equipment & Supplies company this quarter on revenue, margins and earnings-call signals.
Prevest Denpro Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹19 Cr, net profit ₹6 Cr.
Full financials →📊 Revenue & Sales Performance
- →The company posted a 13% sales growth in FY 2025, surpassing the global dental market growth forecast of 6-8%.
- →They aim for higher growth in coming years by expanding diversified product lines like oral care products, 3D printers, and 3D resins.
- →The growth is driven by strengthening domestic market focus while maintaining export and international presence.
- →Efforts to penetrate rural markets and metro areas are ongoing, with improved dealer/distributor appointments.
- →Launch of new products like 3D printers is planned aggressively in the current year to boost revenue.
- →The U.S. subsidiary is expected to contribute as private labeling and contract manufacturing opportunities grow.
- →Management aspires for accelerated growth but acknowledges external uncertainties impacting targets.
- →Long-term vision is to reach over INR 100-125 crores in revenue, though adjusted from earlier IPO projections due to market conditions.
📈 Profitability & Margins
- →The company reported a 13.6% revenue growth for FY 2024-25, with EBITDA margins steady around 39% and PAT growth of 12.5%, signaling stable profitability.
- →Management aims for higher growth through diversification, particularly by expanding into digital dentistry with new products like 3D printers and private labeling.
- →Expectations to surpass current 13% growth when new product lines (oral care, 3D printers/resins) contribute more significantly.
- →Despite aiming for 25-30% revenue growth, external factors like geopolitical events and market challenges make precise forecasts difficult.
- →Long-term vision includes reaching INR 100+ crores and moving toward INR 150 crores revenue, though recent years have seen slowed growth from previous 30% post-IPO CAGR.
- →Margin target remains around the 40% mark, focusing on sustainable profitable growth rather than short-term spikes.
- →Operational efficiencies and R&D investments are expected to support steady, consistent earnings improvement in the future.
🏗️ Capital Expenditure Plans
- →The company is heavily investing in R&D to develop new, innovative dental products, including digital dentistry solutions such as advanced 3D printers and scanners.
- →A new state-of-the-art R&D center has been set up, recognized by the Ministry of Science and Technology.
- →Strategic investment in building the digital dentistry portfolio is a key focus, seeing it as the future growth driver.
- →Incorporation of Axiodent Inc. in the U.S. to strengthen market presence and enable private labeling and local product positioning.
- →Continued investments in operational excellence with lean manufacturing, ERP upgrades, and supply chain optimization for sustainable growth.
- →Private labeling is being pursued actively as a business opportunity to add revenue streams.
- →Focus on expansion through strategic partnerships and penetrating new international markets, including the U.S. and Europe.
- →Measured investment in Oradox (oral care brand) to build long-term brand presence and market share.
💰 Fundraising & Capital Structure
- →There is no explicit mention or confirmation of current or future fundraising through debt or equity in the document.
- →The company emphasizes strong financial health with a robust balance sheet, healthy cash flows, and an optimal debt ratio.
- →Management highlights having sufficient resources and funds available to deploy for diversification and growth.
- →The focus is on using internal funds for R&D, product development, and market expansion rather than external fundraising.
- →The company prefers sustainable, profitable growth without chasing unsustainable numbers that might compromise long-term position.
- →No plans for raising capital through new equity or debt were disclosed during the discussions or Q&A.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Prevest Denpro Ltd Q4 FY25 results?
The company posted a 13% sales growth in FY 2025, surpassing the global dental market growth forecast of 6-8%. - They aim for higher growth in coming years by expanding diversified product lines like oral care products, 3D printers, and 3D resins. - The growth is driven by strengthening domestic market focus while maintaining export and international presence. - Efforts to penetrate rural markets and metro areas are ongoing, with improved dealer/distributor appointments. - Launch of new products like 3D printers is planned aggressively in the current year to boost revenue. - The U.S. The company reported a 13.6% revenue growth for FY 2024-25, with EBITDA margins steady around 39% and PAT growth of 12.5%, signaling stable profitability.
What is Prevest Denpro Ltd share price analysis?
Prevest Denpro Ltd currently shows a neutral. The stock trades at a P/E of 21.4 with a market cap of ₹458 Cr. Investors should review the full earnings analysis for detailed insights.
Is Prevest Denpro Ltd planning capital expenditure?
The company is heavily investing in R&D to develop new, innovative dental products, including digital dentistry solutions such as advanced 3D printers and scanners. - A new state-of-the-art R&D center has been set up, recognized by the Ministry of Science and Technology. - Strategic investment in building the digital dentistry portfolio is a key focus, seeing it as the future growth driver. - Incorporation of Axiodent Inc.
Keep Prevest Denpro Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.